Division of Pediatric Infectious Diseases

Vanderbilt investigators encouraged by early results of placebo-controlled remdesivir trial

A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.

Attendees take part in last week’s online Medical Scientist Training Program seminar.

Medical Scientist Training Program adapts to COVID-19 challenges

The Medical Scientist Training Program has been intentional in approaching the challenges presented by COVID-19.

Katz awarded LEAP Fellowship to improve antibiotic use in Tennessee

Sophie Katz, MD, MPH, is one of four early career infectious diseases physicians in the United States to receive the award, which provides $100,000 of funding support from the Centers for Disease Control and Prevention.

VUMC team aids development of potential antiviral drug for COVID-19

Researchers at Vanderbilt University Medical Center are playing a key role in the development of a potential new antiviral drug to treat COVID-19.

Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.

Vaccine Program receives NIH renewal of VTEU

The Vanderbilt Vaccine Research Program has received a grant from the NIH to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units.

Study tracks causes of high antibiotic prescribing rates in Tennessee

For a few years, Tennessee has been ranked as one of the highest antibiotic prescribing states in the nation, and a recent study showing that fewer than 2% of clinicians were responsible for prescribing 25% of pediatric antibiotics is moving some to action.

1 4 5 6 7 8 11